Genzyme (GENZ) will try to convince shareholders today that its Campath drug could reach annual...

|By:, SA News Editor

Genzyme (GENZ) will try to convince shareholders today that its Campath drug could reach annual sales of $3.5B, not the $700M forecast by Sanofi (SNY). The Campath valuation is the driving force behind Genzyme's claim that Sanofi needs to raise its $69/share offer.